Amylyx is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/20/2021 | Series C-2 | $27.67MM | $xx.xx | $54.1B | 683 Capital Management, Amoon Fund, Bain Capital Life Sciences, Belinda Termeer, Falcon Edge, Marshall Wace, Morningside Ventures, Perceptive Advisors, Polaris Founders Capital, Rock Springs Capital, Tybourne Capital Management, Verition Fund Management, Viking Global Investors, Woodline Partners | |
Price per Share
$xx.xx
Shares Outstanding
3,170,585
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
683 Capital Management, Amoon Fund, Bain Capital Life Sciences, Belinda Termeer, Falcon Edge, Marshall Wace, Morningside Ventures, Perceptive Advisors, Polaris Founders Capital, Rock Springs Capital, Tybourne Capital Management, Verition Fund Management, Viking Global Investors, Woodline Partners
|
||||||
07/20/2021 | Series C-1 | $107.33MM | $xx.xx | $54.1B | 683 Capital Management, Amoon Fund, Bain Capital Life Sciences, Belinda Termeer, Falcon Edge, Marshall Wace, Morningside Ventures, Perceptive Advisors, Polaris Founders Capital, Rock Springs Capital, Tybourne Capital Management, Verition Fund Management, Viking Global Investors, Woodline Partners | |
Price per Share
$xx.xx
Shares Outstanding
10,455,452
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
683 Capital Management, Amoon Fund, Bain Capital Life Sciences, Belinda Termeer, Falcon Edge, Marshall Wace, Morningside Ventures, Perceptive Advisors, Polaris Founders Capital, Rock Springs Capital, Tybourne Capital Management, Verition Fund Management, Viking Global Investors, Woodline Partners
|
||||||
07/01/2020 | Series B | $60.52MM | $xx.xx | $47.79B | Drads Capital, Morningside Ventures | |
Price per Share
$xx.xx
Shares Outstanding
3,565,494
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Drads Capital, Morningside Ventures
|
||||||
08/23/2016 | Series A | $7.73MM | $xx.xx | $2.21B | Als Investment Fund, Lysosomal Therapeutics, Morningside Ventures | |
Price per Share
$xx.xx
Shares Outstanding
6,289,609
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Als Investment Fund, Lysosomal Therapeutics, Morningside Ventures
|